SOUTH SAN FRANCISCO, Calif., Feb. 12, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) today announced that it has entered into definitive agreements with investors to purchase an aggregate of approximately $12 million of units, in a registered public offering, at a price per unit of $2.05. Each unit consists of one share of common stock and 0.5 of a warrant to purchase a share of OXiGENE common stock. The warrants have an exercise price of $2.75 per share, shall be exercisable immediately and will expire five years from the date of issuance. The closing of the offering is expected to take place on or about February 18, 2014, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co., LLC acted as the sole book-running manager for the offering. The securities described above are being offered pursuant to a registration statement (File No. 333-190464) which became effective on February 11, 2014, and a registration statement filed pursuant to Rule 462(b) which became effective on February 12, 2014. When filed with the Securities and Exchange Commission, copies of the final prospectus for the offering can be obtained at the SEC's website at http://www.sec.gov, or from H.C. Wainwright & Co., LLC by e-mailing firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
Safe Harbor Statement
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, and regulatory guidance relative to our clinical programs, achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development and regulatory review, and the availability of additional financing to continue development of our programs.
Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2012.
CONTACT: Investor and Media Contact: email@example.com 650-635-7000